Saudi Arabia

Reimbursed Care Access

Saudi Arabia maintains a highly restrictive controlled‑substances regime: classical recreational and experimental psychedelics (psilocybin, MDMA, DMT, 5‑MeO‑DMT, ibogaine, ayahuasca, mescaline, 2C‑X) are criminalized and permitted only for approved medical/scientific research under tight SFDA and narcotics law controls. Ketamine is widely used in clinical practice as an anaesthetic and for off‑label psychiatric uses in healthcare settings; the esketamine product Spravato is registered with the Saudi Food and Drug Authority (SFDA) and may be supplied only under risk‑management requirements and restricted administration settings. Public reimbursement for novel psychedelic therapeutics (e.g., Spravato) is limited and depends on hospital formulary and payer decisions; most access in the Kingdom occurs in licensed hospitals/clinics under medical supervision rather than via community prescriptions.